🔥🐔 BizChicken 🐔🔥
Companies Similar to Ovid Therapeutics Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Biogen Inc.
TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, FAMPYRA, SPINRAZA, FUMADERM, BENEPALI, ADUHELM, IMRALDI, FLIXABI, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS
Biogen Inc. focuses on discovering, developing, manufacturing, and delivering therapies for neurological and neurodegenerative diseases, including multiple sclerosis, spinal muscular atrophy, plaque psoriasis, Alzheimer's disease, and various cancers and autoimmune conditions.
About | About | Vision/Values | Leadership | Foundation | Contact | Careers | Careers | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Benefits | Careers | Careers | Careers | Careers | About | About | About | About
Symbol: BIIB
Recent Price: $150.19
Industry: Drug Manufacturers - General
CEO: Mr. Christopher A. Viehbacher
Sector: Healthcare
Employees: 7570
Address: 225 Binney Street, Cambridge, MA 02142
Phone: 617 679 2000
Leadership
- Christopher A. Viehbacher, President and Chief Executive Officer
- Susan H. Alexander, Chief Legal Officer
- Ginger Gregory, Ph.D., Chief Human Resources Officer
- Jane Grogan, Ph.D., Head of Research
- Rachid Izzar, Head of Global Product Strategy & Commercialization
- Adam Keeney, Head of Corporate Development
- Michael McDonnell, Chief Financial Officer
- Nicole Murphy, Head of Pharmaceutical Operations and Technology
- Priya Singhal, M.D., M.P.H., Head of Development and Interim Chief Medical Officer
- Alisha Alaimo, President, Head of North America
- Stephen Amato, Head of Investor Relations
- Natacha Gassenbach, Head of Corporate Affairs, Chief Communications Officer
- Fraser Hall, President, Head of Intercontinental Region
- Wolfram Schmidt, President, Head of Europe
- Kendra Thomas, Head of Global Workforce Diversity, Equity & Inclusion (DE&I)
- Caroline Dorsa, Chair of the Board
- Maria C. Freire, Ph.D., Director
- William A. Hawkins, Director
- Susan Langer, Director
- Jesus B. Mantas, Director
- Lloyd B. Minor, M.D., Director
- Monish Patolawala, Director
- Eric K. Rowinsky, M.D., Director
- Stephen A. Sherwin, M.D., Director
Last updated: 2024-12-31
Genelux Corporation
Olvi-Vec
Genelux Corporation is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for tough-to-treat cancers, with a lead product candidate, Olvi-Vec.
Management | Directors | About | Management | Directors | About | Contact | Contact | Contact | Careers | Careers | About | About | About | About | About
Symbol: GNLX
Recent Price: $2.40
Industry: Biotechnology
CEO: Mr. Thomas Zindrick J.D.
Sector: Healthcare
Employees: 24
Address: 2625 Townsgate Road, Westlake Village, CA 91361
Phone: 858 483 0024
Leadership
- Bob Smith, CTO
- THOMAS ZINDRICK, J.D., Chairman
- JAMES L. TYREE, MBA, Lead Independent Director
- MARY MIRABELLI, MBA, Chair, Nominating and Corporate Governance Committee
- JOHN THOMAS, M.A., MBA, Ph.D., Chair, Audit Committee
- JOHN SMITHER, Chair, Compensation Committee
- Alice Johnson, CEO
- Carol Davis, CFO
- David Wilson, Chairman
- Eva Brown, Director
Last updated: 2024-12-31
ORIC Pharmaceuticals, Inc.
ORIC-533, ORIC-944, ORIC-114
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of cancers, focusing on overcoming resistance in chemotherapy and immunotherapy. Their product candidates target various cancer resistance mechanisms, including prostate cancer and epidermal growth factor receptor mutations.
Symbol: ORIC
Recent Price: $8.17
Industry: Biotechnology
CEO: Dr. Jacob M. Chacko M.B.A., M.D.
Sector: Healthcare
Employees: 107
Address: 240 East Grand Avenue, South San Francisco, CA 94080
Phone: 650 388 5600
Last updated: 2024-12-31
Omeros Corporation
Narsoplimab
Omeros Corporation is a commercial-stage biopharmaceutical company that focuses on discovering, developing, and commercializing therapeutics for inflammation, immune-related cancers, and addictive disorders.
Symbol: OMER
Recent Price: $9.74
Industry: Biotechnology
CEO: Dr. Gregory A. Demopulos M.D.
Sector: Healthcare
Employees: 198
Address: The Omeros Building, Seattle, WA 98119
Phone: 206 676 5000
Last updated: 2024-12-31
Pyxis Oncology, Inc.
PYX-106, PYX-102, PYX-201, PYX-202, PYX-203
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.
Symbol: PYXS
Recent Price: $1.56
Industry: Biotechnology
CEO: Dr. Lara S. Sullivan M.D., MBA
Sector: Healthcare
Employees: 55
Address: 35 Cambridgepark Drive, Cambridge, MA 02140
Phone: 617 221 9059
Last updated: 2024-12-31
Abivax SA American Depositary Shares
obefazimod
ABIVAX Société Anonyme is a clinical-stage biotechnology company developing therapeutics to modulate the immune response for chronic inflammatory diseases. Their lead drug candidate, obefazimod, is in Phase 3 clinical trials for ulcerative colitis.
About | Vision/Values | History | Leadership | Contact | About | About
Symbol: ABVX
Recent Price: $7.05
Industry: Biotechnology
CEO: Mr. Marc M. P. de Garidel M.B.A.
Sector: Healthcare
Employees: 62
Address: 7-11 boulevard Haussmann, Paris, null 75009
Phone: 33 1 53 83 09 63
Leadership
- Marc de Garidel, MBA, Chief Executive Officer
- Didier Blondel, EVP, Chief Financial Officer & Board Secretary
- Fabio Cataldi, MD, Chief Medical Officer
- Ida Hatoum, Chief People Officer, Chief Compliance Officer
- David Zhang, PhD, Chief Strategy Officer
- Pierre Courteille, Pharmacist, MBA, Chief Business Officer
- Didier Scherrer, PhD, Chief Scientific Officer
- Jérôme Denis, PhD, EVP, Process Development & Manufacturing
- Nadège Briancon-Eris, PhD, Senior Vice President, Global Head of Program Management
- Sylvie Grégoire, PharmD, Chair of the Board
- Corinna zur Bonsen-Thomas, Co-founder and CEO of RetInSight; Former General Counsel at Baxter/Baxalta International
- Philippe Pouletty, MD, Founder of Abivax; Managing Partner of Truffle Capital
- June Lee, MD FACCP, Venture Partner at 5AM Ventures
- Kinam Hong, MD, MBA, CFA, Partner at the Crossover Fund Sofinnova
- Troy Ignelzi, CFO of Rapport Therapeutics
- Camilla Soenderby, Board Member of BB Biotech, F2G, and Affibody; Member of Novo Holdings Advisory Group; Industrial Advisor for EQT
- Mary Mantock, Senior Vice President, Global Head of Regulatory Affairs
- Hema Keshava, Senior Vice President, Finance
- Cristina Damatarca, MD, PgD, Senior Vice President, Global Head of Drug Safety and Pharmacovigilance
- Patrick Malloy, Senior Vice President, Investor Relations
- Douglas Jacobstein, MD, Senior Vice President, Global Head of Clinical Development
- Jennifer Fine, ScD, Senior Vice President, Global Head of HEOR and RWE
- Kevin Shan, PhD, Vice President, Global Head of Biometrics
- Chris Rabbat, PhD, Vice President, Global Head of Medical Affairs
- Ana Sharma, MPH, Vice President, Global Head of Quality
- Sophie LaCourrege, Vice President, HR Business Partner, Engagement and Culture
Last updated: 2024-12-31
Axsome Therapeutics, Inc.
AXS-05, AXS-07, AXS-12, AXS-14
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system disorders such as major depressive disorder, migraine, narcolepsy, and fibromyalgia.
About | Leadership | Directors | About | About | About | About | About | About | Contact | Careers | Careers | About | About
Symbol: AXSM
Recent Price: $84.78
Industry: Biotechnology
CEO: Dr. Herriot Tabuteau M.D.
Sector: Healthcare
Employees: 589
Address: 22 Cortlandt Street, New York, NY 10007
Phone: 212 332 3241
Leadership
- Herriot Tabuteau, MD, CHIEF EXECUTIVE OFFICER
- Nick Pizzie, CPA, MBA, CHIEF FINANCIAL OFFICER
- Mark Jacobson, MA, CHIEF OPERATING OFFICER
- Hunter Murdock, Esq., GENERAL COUNSEL
- ari Maizel, Executive Vice President, Head of Commercial
- Mark Coleman, MD, DIRECTOR
- Roger Jeffs, PhD, DIRECTOR
- Susan Mahony, PhD, MBA, DIRECTOR
- Mark Saad, DIRECTOR
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
Nurix Therapeutics, Inc.
NX-2127, NX-5948, NX-1607, NX-0255
Nurix Therapeutics, Inc. is a biopharmaceutical company that focuses on developing small molecule therapies for cancer and immune disorders, with products targeting BTK and CBL-B proteins. The company collaborates with Gilead Sciences and Sanofi.
Symbol: NRIX
Recent Price: $18.64
Industry: Biotechnology
CEO: Dr. Arthur T. Sands M.D., Ph.D.
Sector: Healthcare
Employees: 284
Address: 1700 Owens Street, San Francisco, CA 94158
Phone: 415 660 5320
Last updated: 2024-12-31
Ocuphire Pharma, Inc.
Nyxol
Ocuphire Pharma, Inc. is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders.
Symbol: OCUP
Recent Price: $1.17
Industry: Biotechnology
CEO: Mr. George Magrath M.B.A., M.D., M.S.
Sector: Healthcare
Employees: 14
Address: 37000 Grand River Avenue, Farmington Hills, MI 48335
Phone: 248 681 9815
Last updated: 2024-12-31
Omega Therapeutics, Inc.
OMEGA Epigenomic Programming platform
Omega Therapeutics, Inc. is a development-stage biopharmaceutical company leveraging its OMEGA Epigenomic Programming platform to utilize the power of epigenetics for therapeutic interventions across various diseases.
About | Vision/Values | Leadership | Leadership | About | Contact | Contact | About | About
Symbol: OMGA
Recent Price: $0.80
Industry: Biotechnology
CEO: Mr. Mahesh Karande
Sector: Healthcare
Employees: 93
Address: 20 Acorn Park Drive, Cambridge, MA 02140
Phone: 617 949 4360
Leadership
- Mahesh Karande, President & Chief Executive Officer
- Kaan Certel, Ph.D., Chief Business Officer
- Jennifer Nelson, Ph.D., Senior Vice President, Research
- Tony Mullin, Chief People Officer
- Barbara Chan, Senior Vice President, Finance and Chief Accounting Officer
- Lisamarie Fahy, Senior Vice President, Clinical Development Operations
- Joe Newman, Ph.D., Senior Vice President, Early Discovery
- Jeff Atkinson, Ph.D., Vice President, Technical Operations
- Eva Stroynowski, Senior Vice President, Investor Relations and Corporate Affairs
Last updated: 2024-12-31
Ovid Therapeutics Inc.
OV101, OV329, OV350, OV882, OV815
Ovid Therapeutics Inc., a biopharmaceutical company based in New York, is dedicated to developing impactful medicines for neurological disorders. They have a range of drug candidates like OV101 and are involved in various clinical trials.
Our Story | Leadership | Directors | About | Our Story | Contact | About | About | About | About | About | Culture | Culture | Vision/Values | Culture | About | Culture | Culture | About | Jobs | Careers | Careers | Jobs | About | About | About | Careers | Vision/Values | About | About | About | About | About | About
Symbol: OVID
Recent Price: $0.96
Industry: Biotechnology
CEO: Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Sector: Healthcare
Employees: 40
Address: 1460 Broadway, New York, NY 10036
Phone: 646 661 7661
Leadership
- Jeremy M. Levin, D.Phil, MB BChir, Chief Executive Officer and Chairman
- Meg Alexander, President and Chief Operating Officer
- Zhong Zhong, Ph.D., Chief Scientific Officer
- Jeffrey Rona, Chief Business and Financial Officer
- Amanda Banks, M.D., Chief Development Officer
- Julia Tsai, Ph.D., Senior Vice President of Clinical Development
- Karen Bernstein, Ph.D., Director, Chair of the Compensation Committee, Member of the Audit and Nominating and Corporate Governance Committees
- Barbara G. Duncan, MBA, Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee
- Bart Friedman, J.D., Lead Independent Director, Chair of the Nominating and Corporate Governance Committee, Member of the Audit and Compensation Committees
- Michael Poole, M.D., FACP, Director, Member of the Audit and Compensation Committees
- Kevin Fitzgerald, Ph.D., Director, Member of the Nominating and Corporate Governance Committee
Last updated: 2024-12-31
Scopus BioPharma Inc.
Duet Platform
Scopus Bio Pharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics for serious diseases with lead programs in immuno-oncology gene therapy.
Symbol: SCPS
Recent Price: $0.00
Industry: Biotechnology
CEO: Dr. Alan D. Horsager Ph.D.
Sector: Healthcare
Employees: 13
Address: 420 Lexington Avenue, New York, NY 10170
Phone: 212 479 2513
Last updated: 2024-12-31
Trevena, Inc.
OLINVYK (Oliceridine) injection
Trevena, Inc. is a biopharmaceutical company focused on developing and commercializing novel medicines for central nervous system disorders, with products like OLINVYK and collaborations such as with Imperial College London.
Symbol: TRVN
Recent Price: $1.50
Industry: Biotechnology
CEO: Ms. Carrie L. Bourdow
Sector: Healthcare
Employees: 23
Address: 955 Chesterbrook Boulevard, Chesterbrook, PA 19087
Phone: 610 354 8840
Leadership
- Carrie L. Bourdow, President and Chief Executive Officer
- Mark A. Demitrack, MD, Senior Vice President, Chief Medical Officer
- Barry Shin, Executive Vice President, Chief Operating Officer and Chief Financial Officer
- Robert T. Yoder, Senior Vice President, Chief Business Officer, Head of Commercial Operations & Chief Compliance Officer
- Scott Braunstein, M.D., Lead Independent Director
- Dr. Mark Corrigan, Acting CEO
- Marvin H. Johnson, Jr., Board Member
- Jake R. Nunn, Board Member
- Anne M. Phillips, M.D., Board Member
- Barbara Yanni, Board Member
Last updated: 2024-12-31
Verve Therapeutics, Inc.
VERVE-101
Verve Therapeutics, Inc. is a genetic medicines company developing gene editing treatments for cardiovascular diseases, primarily through its lead product VERVE-101.
Symbol: VERV
Recent Price: $5.54
Industry: Biotechnology
CEO: Dr. Sekar Kathiresan M.D.
Sector: Healthcare
Employees: 255
Address: 500 Technology Square, Cambridge, MA 02139
Phone: 617 603 0070
Leadership
- Andrew Ashe, President, Chief Operating Officer and General Counsel
- Victoria Bartlett, Vice President, Program and Alliance Management
- Dan Balian, Associate Director, Supply Chain Management
- Allen Barrett, Director, Corporate Counsel
Last updated: 2024-12-31
Nuvation Bio Inc.
NUV-422
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focusing on the development of therapeutic candidates for oncology, such as NUV-422, a small molecule inhibitor targeting cyclin-dependent kinases, among other innovative treatments.
Symbol: NUVB
Recent Price: $2.62
Industry: Biotechnology
CEO: Dr. David T. Hung M.D.
Sector: Healthcare
Employees: 51
Address: 1500 Broadway, New York, NY 10036
Phone: 332 208 6102
Last updated: 2024-12-31
Abeona Therapeutics Inc.
EB-101
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa.
Symbol: ABEO
Recent Price: $5.61
Industry: Biotechnology
CEO: Dr. Vishwas Seshadri M.B.A., Ph.D.
Sector: Healthcare
Employees: 84
Address: 1330 Avenue of the Americas, New York, NY 10019
Phone: 646 813 4701
Last updated: 2024-12-31
Immix Biopharma, Inc.
IMX-110, IMX-111, IMX-120
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company developing tissue-specific therapeutics for oncology and inflammation, with clinical trials across the United States and Australia.
Symbol: IMMX
Recent Price: $2.36
Industry: Biotechnology
CEO: Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D.
Sector: Healthcare
Employees: 14
Address: 11400 West Olympic Boulevard, Los Angeles, CA 90064
Phone: 310 651 8041
Last updated: 2024-12-31
Nuvectis Pharma, Inc.
NXP800, NXP900
Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.
Symbol: NVCT
Recent Price: $5.14
Industry: Biotechnology
CEO: Mr. Ron Bentsur M.B.A.
Sector: Healthcare
Employees: 13
Address: 1 Bridge Plaza, Fort Lee, NJ 07024
Phone: 201 614 3150
Last updated: 2024-12-31
Ventyx Biosciences, Inc.
VTX958
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule product candidates for the treatment of inflammatory diseases and autoimmune disorders. Key products include VTX958 for immune-mediated diseases, VTX002 for ulcerative colitis, and VTX2735 for systemic inflammatory diseases.
Symbol: VTYX
Recent Price: $2.23
Industry: Biotechnology
CEO: Dr. Raju S. Mohan Ph.D.
Sector: Healthcare
Employees: 73
Address: 662 Encinitas Boulevard, Encinitas, CA 92024
Phone: 760 593 4832
Last updated: 2024-12-31